AMENDMENT TRANSMITTAL LETTER (Small Entity) Applicant(s): George M. Halow					Docket No. A-8636	
Application No. 10/748,185	Filing Date December 31, 2003	Examiner Amy A. Lewis	Customer 1 20741	No.	Group Art Unit 1614	Confirmation No. 5571
Invention: PAPOS TION AND METHOD FOR TREATMENT OF HEPATIC ENCEPHALOPATHY						
COMMISSIONER FOR PATENTS:						
Transmitted herewith is an amendment in the above-identified application. Applicant claims small entity status. See 37 CFR 1.27 The fee has been calculated and is transmitted as shown below.						
CLAIMS AS AMENDED						
	CLAIMS REMAINING	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	\prod	RATE	ADDITIONAL FEE
TOTAL CLAIMS	32 -	25 =	7	×	\$25.00	\$175.00
INDEP. CLAIMS	3 -	3 =	0	×	\$100.00	\$0.00
Multiple Depender	nt Claims (check if app	olicable)				\$0.00
	·	TOTAL ADDITIONAL F	FEE FOR THIS AN	IENI	DMENT	\$175.00
No additional fee is required for amendment. Please charge Deposit Account No. in the amount of A check in the amount of \$175.00 to cover the filing fee is enclosed. The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 08-2455 Any additional filing fees required under 37 C.F.R. 1.16. Any patent application processing fees under 37 CFR 1.17. Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. Warnington Pto-2038 Dated: Workubu Boos						
cc:	Signature of Person Mailing Correspondence Typed or Printed Name of Person Mailing Correspondence					



STATES PATENT AND TRADEMARK OFFICE

In re the application of:

George M. HALOW

Group Art Unit: 1614

Serial No: 10/748,185

Examiner: Amy A. Lewis

Filed : December 31, 2003

For : COMPOSITION AND METHOD FOR TREATMENT

OF HEPATIC ENCEPHALOPATHY

AMENDMENT UNDER 35 USC \$115

C \$115 11/02/2005 HBEYENE1 00000045 10748185

01 FC:2202

175.00 OP

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The Examiner has rejected Claims 15-25 under 35 USC \$112, second paragraph, referring to the claim structure. The phrase "method or composition" in these claims was a drafting error and has been modified to correspond to the relevant dependencies of each claim. Withdrawal of this rejection is accordingly requested.

The Examiner has further rejected Claims 1 and 2 under 35 USC \$102(b) over Roblin et al. <u>Gastroenterol Clin Biol 18</u>:1146 (1994). The Examiner cites only the title of the article, "Use of polyethylene glycol 4000 in hepatic encephalopathy related to digestive hemorrhages", as grounds for the rejection, although a copy of the article itself (presumably translated from the French) was provided to Applicant.

The full article describes a method for treatment of ruptured esophageal varicose veins associated with portal hypertension in a cirrhosis patient with hepatic encephalopathy (HE), comprising the administration of 2 liters of a PEG 4000 (Fortrans 7) via a gastric probe over two hours to evacuate intestinal blood resulting from acute digestive hemorrhage. (Fortrans is an isotonic colonic lavage solution which contains PEG 4000 and electrolyte, see attached printout (http://www.emergingp.com/main/fortrans.asp) of Emerging Pharma website; typically, such PEG lavage solutions contain from about